Around 70% to 80% of patients with breast cancer have hormone receptor–positive (HR+) disease—meaning that their tumors express ER and/or progesterone receptor (PgR)—and most of these have ER-driven tumors at diagnosis (1). This evidence concerns the gene ESR1 and breast cancer.